China’s WuXi Commits To Large Expansion Of Research, Reagent Spending
This article was originally published in PharmAsia News
China's largest drug-research contractor, WuXi PharmaTech, plans to increase spending, perhaps doubling it, on laboratory equipment and reagents and other source materials, the company announced. The spending expansion, from the current $41.7 million, is being done to enlarge its research capacity and support U.S.-based AppTec Laboratory Services, whose $151 million purchase by WuXi just received U.S. Federal Trade Commission approval. To pay for the expansion, WuXi has asked for concessions by its suppliers. (Click here for more
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Commissioner Hahn’s tweet announcing a return to inspections, while not a new policy, may be signal that FDA understands sponsor concerns with the agency’s limited ability to conduct onsite inspections. Effort may be aimed at reassuring industry even as CRLs related to manufacturing increase.
Rushed final rule seeking to impose draconian cuts on drug reimbursement rates in the Medicare Part B program is certain to face legal and political obstacles. But the data included on international price benchmarks will still have an impact.